EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Antenatal Corticosteroids in Gestational Diabetes: A Systematic Review of Glycemic Response and Management Strategies

Alexandra Katz iD, Aidan Shulkin, Samantha Jacobson, Chella Price, Michael A Tsoukas iD, Isabella Albanese, Agnieszka Majdan, Jill Pancer, Ariane Godbout, Kaberi Dasgupta iD, Anne-Sophie Brazeau iD, Tricia Peters

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11006-11031

DOI: 10.1111/dom.71311 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.09.2026. Verfasst von Alexandra Katz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Diabetes, Gestational, Blood Glucose, Adrenal Cortex Hormones. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH, CIHR, Diabetes Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antenatal corticosteroids (ACS) promote foetal lung maturation in pregnancies at risk of preterm birth; however, in gestational diabetes mellitus (GDM), they can exacerbate maternal glycemia and contribute to adverse neonatal outcomes. Clinical guidelines offer limited direction on optimal treatment adjustment.

Objectives

To synthesize the evidence on glycaemic responses and management strategies following ACS exposure in individuals with GDM.

Methods

A systematic review of Embase, MEDLINE and CENTRAL in October 2025 in accordance with PRISMA guidelines. Studies reporting on glycaemic outcomes and/or management strategies following ACS exposure in individuals with GDM were included.

Results

Twenty studies were included. Maternal glycemia rose predictably after ACS, with hyperglycaemia typically emerging within 9–16 h, peaking over the subsequent 24–72 h and often persisting up to 5 days. Among individuals managed with medical nutrition therapy or oral hypoglycaemic agents at baseline, insulin initiation ranged from 13% to 91%. Among those already using insulin, 67%–88% required dose escalation, with mean increases typically ranging from 47% to 91%. Pregnancy‐adapted intravenous insulin (IVI) pathways reported higher time‐in‐range and fewer hyperglycaemic/hypoglycaemic events than adult IVI protocols. However, emerging evidence suggests that structured, pregnancy‐specific subcutaneous insulin protocols may achieve comparable or improved glycaemic control.

Conclusions

ACS exposure in GDM is associated with a predictable but variable, transient deterioration in maternal glycaemia. GDM‐specific evidence suggests that structured pregnancy‐adapted monitoring and insulin‐adjustment pathways may help attenuate post‐ACS hyperglycaemia. However, the evidence remains heterogeneous and largely observational. Prospective studies are needed to validate GDM‐specific algorithms, clarify thresholds for insulin initiation or escalation and define indications for subcutaneous versus IVI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes, GestationalBlood GlucoseAdrenal Cortex HormonesHumansFemalePregnancyHypoglycemic AgentsHyperglycemiaInsulinPrenatal Care

Stichwörter der Autor:innen

antenatalcorticosteroidgestational diabetesglycaemiainsulinpregnancysystematic review

Substanzen

Blood GlucoseAdrenal Cortex HormonesHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
  • Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
  • Division of Endocrinology and Metabolism, McGill University Health Centre, Montreal, Quebec, Canada.
  • Division of Endocrinology and Metabolism, Jewish General Hospital, Montreal, Quebec, Canada.

ORCID-Profile: Alexandra Katz, Michael A Tsoukas, Kaberi Dasgupta, Anne-Sophie Brazeau

Förderung

  • NIH
  • CIHR
  • Diabetes Canada
  • UK Medical Research Council
  • Lawson Foundation
  • Fonds de recherche du québec en santé
  • National Institutes of Health
  • Canadian Institutes of Health Research

Zitieren

APA

Katz, A., Shulkin, A., Jacobson, S., Price, C., Tsoukas, M. A., Albanese, I., Majdan, A., Pancer, J., Godbout, A., Dasgupta, K., Brazeau, A. S., & Peters, T. (2026). Antenatal Corticosteroids in Gestational Diabetes: A Systematic Review of Glycemic Response and Management Strategies. Diabetes, Obesity and Metabolism, 28(12), 11006-11031. https://doi.org/10.1111/dom.71311

Vancouver

Katz A, Shulkin A, Jacobson S, Price C, Tsoukas MA, Albanese I, et al. Antenatal Corticosteroids in Gestational Diabetes: A Systematic Review of Glycemic Response and Management Strategies. Diabetes, Obesity and Metabolism. 2026;28(12):11006-11031. doi:10.1111/dom.71311

BibTeX
@article{Katz2026,
  author = {Katz, Alexandra and Shulkin, Aidan and Jacobson, Samantha and Price, Chella and Tsoukas, Michael A and Albanese, Isabella and Majdan, Agnieszka and Pancer, Jill and Godbout, Ariane and Dasgupta, Kaberi and Brazeau, Anne-Sophie and Peters, Tricia},
  title = {Antenatal Corticosteroids in Gestational Diabetes: A Systematic Review of Glycemic Response and Management Strategies},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11006--11031},
  doi = {10.1111/dom.71311}
}
Kostenlos starten →